Lansoprazole - Apricus Biosciences

Drug Profile

Lansoprazole - Apricus Biosciences

Alternative Names: PrevOnco

Latest Information Update: 12 Apr 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator FasTrack Pharmaceuticals
  • Developer Apricus Biosciences
  • Class Antiulcers; Benzimidazoles; Gastric antisecretories; Pyridines; Small molecules; Sulfoxides
  • Mechanism of Action Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Liver cancer

Most Recent Events

  • 12 Jul 2018 Biomarkers information updated
  • 27 Aug 2015 No recent reports on development identified - Phase-II for Liver cancer (First-line therapy) in USA (PO)
  • 19 Apr 2012 Lansoprazole - Apricus Biosciences is available for licensing as of 13 Mar 2012. http://www.apricusbio.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top